2024-19726. Medical Devices; Orthopedic Devices; Classification of the Intervertebral Body Graft Containment Device  

  • Table 1—Intervertebral Body Graft Containment Device Risks and Mitigation Measures

    Identified risks to health Mitigation measures
    Adverse tissue reaction Design characteristics, Biocompatibility evaluation, Sterilization/reprocessing validation, and Labeling.
    Infection Sterilization/reprocessing validation and Labeling.
    Loosening/migration due to device failure or failure at the bone-implant interface Design characteristics, Clinical performance testing, Non-clinical performance testing, Biocompatibility evaluation, and Labeling.
    Tissue injury Labeling.
    Pseudarthrosis due to device failure or failure at the bone-implant interface Clinical performance testing, Non-clinical performance testing, Biocompatibility evaluation, and Labeling.
    Adverse clinical sequelae Clinical performance testing and Labeling.
    Use error/Improper device use Labeling.

Document Information

Effective Date:
9/3/2024
Published:
09/03/2024
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final amendment; final order.
Document Number:
2024-19726
Dates:
This order is effective September 3, 2024. The classification was applicable on September 18, 2020.
Pages:
71157-71159 (3 pages)
Docket Numbers:
Docket No. FDA-2024-N-3994
Topics:
Medical devices
PDF File:
2024-19726.pdf
CFR: (1)
21 CFR 888